Compare iShares MSCI Indonesia ETF (EIDO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Mesoblast Limited — how do they compare? iShares MSCI Indonesia ETF trades at $11.78 (market cap $409.22M), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 4.3× iShares MSCI Indonesia ETF's market cap, and iShares MSCI Indonesia ETF is more actively traded (879,527 versus 239,027). Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Indonesia ETF for 75 Days and Mesoblast Limited for 14 Days on average.
| EIDO | MESO | |
|---|---|---|
Market Cap | $409.22M | $1.75B |
Volume | 879,527 | 239,027 |
52-Week High | $19.22 | $20.96 |
52-Week Low | $10.80 | $13.19 |
Typical Hold Time | 75 Days | 14 Days |
Sector | — | Health |
Enterprise Value | — | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EIDO (iShares MSCI Indonesia ETF) trades at $11.86, down 0.59% with bearish technical signals from moving averages. The ETF faces headwinds as foreign capital rotates away from Asian markets, with recent news highlighting Indonesia's failure to benefit from commodity gains despite attractive valuations. Trading volume declined 21% below average, indicating reduced investor interest.
The outlook remains cautious with technical weakness outweighing valuation appeal. Key risks include heavy financial sector exposure (44%) and limited EPS growth potential. Seasonal patterns historically favor July-August performance, but current market dynamics suggest continued pressure on Indonesian equities amid regional capital outflows.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
